Please ensure Javascript is enabled for purposes of website accessibility

Will Moderna's Next Earnings Report Top Its Billion-Dollar First Quarter?

By Adria Cimino - Updated Jun 23, 2021 at 8:26AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Coronavirus vaccine contracts so far represent billions of dollars in sales.

Moderna (MRNA -1.41%) recently posted its first profit. That's thanks to billions of dollars in sales of its coronavirus vaccine in the first quarter. In this Motley Fool Live video recorded on May 28, 2021, Healthcare and Cannabis Bureau Editor and Analyst Olivia Zitkus and Fool.com contributor Adria Cimino discuss how much revenue to expect from Moderna this year -- and the company's near-term priorities.

Olivia Zitkus: Moderna, they had announced that it signed contracts worth as much as 18 billion for 2021, right? How does that first quarter of revenue, that 1.7 billion, fit into that bigger number?

Adria Cimino: Well, I think it shows just one full quarter of the vaccine, its first full quarter. I think that moving forward, we're going to see a lot more. I expect the next quarters to be even stronger as they get the whole production and delivery ramp-up going. I would expect to see things strengthening as we go along. Now the next focus for Moderna really needs to be the manufacturing ramp-up. The deals for next year, getting the booster. They mentioned that the booster probably will be ready for fall, so all of that is going to be crucial at this point to moving along. We'll have to be monitoring that in the coming months.

Adria Cimino has no position in any of the stocks mentioned. Olivia Zitkus owns shares of Moderna Inc. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$171.81 (-1.41%) $-2.46

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
390%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.